Forbes: Regeneron’s high-powered cholesterol shot, Praluent, just got recommended 13 to 3 for approval by a panel convened to advise the Food and Drug Administration. But there were so many caveats that insurers are probably doing a happy dance about their likely ability to restrict its use. Amgen AMGN -1.07%, whose rival drug Repatha goes before the same panel tomorrow, has reason to be nervous.
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe Nowi360Gov is an intelligent network of websites and e-newsletters that provides government business, policy and technology leaders with a single destination for the most important news and analysis regarding their agency strategies and initiatives.
Telephone: 202.760.2280
Toll Free: 855.i360.Gov
Fax: 202.697.5045
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe Now